Portfolio Grader currently ranks Evolent Health Inc (NYSE:EVH) a Sell. The approach to investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current Portfolio Grader recommendation on the shares has been in place for 4 months.

Portfolio Grader currently ranks Evolent Health Inc (NYSE:EVH) a Sell. The approach to investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current Portfolio Grader recommendation on the shares has been in place for 4 months.

Evolent Health Inc (NYSE:EVH) is a component of the 24 company Health Care Technology GICS industry group, which is a segment of the 782 company GICS Health Care sector. EVH has a market value of $0.8 billion which is in the top half of its industry group. The current Portfolio Grader ranking for EVH puts it 23 among the 24 companies in this industry group, a position that is well below-average; squarely in the bottom quartile of the sector with a ranking of 688 among the 782 companies in the sector, and number 4,187 in the nearly 5,000 company Portfolio Grader universe.

With a $0.9 billion market value, Evolent Health Inc (NYSE:EVH) ranks in the top half of its industry group, Health Care Technology, and in the upper half of its sector group, Health Care, in market value. From the prospective of investment attractiveness, the stock's Portfolio Grader ranking currently places it 22 among the 24 companies in this industry group, a spot that is well below-average; squarely in the bottom quartile of the sector with a ranking of 601 among the 785 companies in the sector, and number 3,713 in the nearly 5,000 company Portfolio Grader universe.

With a $1.1 billion market value, Evolent Health Inc (NYSE:EVH) ranks in the upper half of its industry group, Health Care Technology, and in the top half of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's current Portfolio Grader ranking places it 19 among the 25 companies in this industry group, a spot that is well below-average; in the third quartile of the sector with a ranking of 571 among the 783 companies in the sector, and number 3,697 in the nearly 5,000 company Portfolio Grader universe.

Currently, Evolent Health Inc (NYSE:EVH) has a Sell using Louis Navellier's methodology for investing and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for 2 months.

Evolent Health Inc (NYSE:EVH) ranks in the upper half of its industry group, Health Care Technology, and in the top half of its sector group, Health Care, with a market value of $1.1 billion. From an investment attractiveness vantage point, EVH is ranked in the third quartile of the sector with a ranking of 559 among the 783 companies in the sector; the stock's current Portfolio Grader ranking places it 21 among the 26 companies in this industry group, a position that is well below-average and number 3,655 in the 5000 company Portfolio Grader company universe.

The current recommendation of Sell for Evolent Health Inc (NYSE:EVH) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. EVH has maintained this ranking for the last month.

The current recommendation of Sell for Evolent Health Inc (NYSE:EVH) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. EVH has maintained this ranking for the last month.